EPO revokes AstraZeneca’s pulmonary disease patent
06 May 2008
Eklavya Gupte, London
One of AstraZeneca’s European patents covering Symbicort, a drug that treats pulmonary disease, has been revoked by the EPO following an appeal by generic manufacturers Norton Healthcare and Generics UK
The patent (EPB1014993) is one of two patents covering the Symbicort combination (formoterol and budesonide) used to treat chronic obstructive pulmonary disease.
The expiry date for the patent is 2018. The other patent covering the drug (EPB1210943) faces a separate...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial